145 related articles for article (PubMed ID: 27764775)
1. Complement inhibitor CSMD1 acts as tumor suppressor in human breast cancer.
Escudero-Esparza A; Bartoschek M; Gialeli C; Okroj M; Owen S; Jirström K; Orimo A; Jiang WG; Pietras K; Blom AM
Oncotarget; 2016 Nov; 7(47):76920-76933. PubMed ID: 27764775
[TBL] [Abstract][Full Text] [Related]
2. Loss of CSMD1 expression disrupts mammary duct formation while enhancing proliferation, migration and invasion.
Kamal M; Holliday DL; Morrison EE; Speirs V; Toomes C; Bell SM
Oncol Rep; 2017 Jul; 38(1):283-292. PubMed ID: 28534981
[TBL] [Abstract][Full Text] [Related]
3. miR-10b exerts oncogenic activity in human hepatocellular carcinoma cells by targeting expression of CUB and sushi multiple domains 1 (CSMD1).
Zhu Q; Gong L; Wang J; Tu Q; Yao L; Zhang JR; Han XJ; Zhu SJ; Wang SM; Li YH; Zhang W
BMC Cancer; 2016 Oct; 16(1):806. PubMed ID: 27756250
[TBL] [Abstract][Full Text] [Related]
4. The expression of the von Hippel-Lindau gene product and its impact on invasiveness of human breast cancer cells.
Zia MK; Rmali KA; Watkins G; Mansel RE; Jiang WG
Int J Mol Med; 2007 Oct; 20(4):605-11. PubMed ID: 17786294
[TBL] [Abstract][Full Text] [Related]
5. Complement inhibitor CSMD1 modulates epidermal growth factor receptor oncogenic signaling and sensitizes breast cancer cells to chemotherapy.
Gialeli C; Tuysuz EC; Staaf J; Guleed S; Paciorek V; Mörgelin M; Papadakos KS; Blom AM
J Exp Clin Cancer Res; 2021 Aug; 40(1):258. PubMed ID: 34404439
[TBL] [Abstract][Full Text] [Related]
6. Characterization CSMD1 in a large set of primary lung, head and neck, breast and skin cancer tissues.
Ma C; Quesnelle KM; Sparano A; Rao S; Park MS; Cohen MA; Wang Y; Samanta M; Kumar MS; Aziz MU; Naylor TL; Weber BL; Fakharzadeh SS; Weinstein GS; Vachani A; Feldman MD; Brose MS
Cancer Biol Ther; 2009 May; 8(10):907-16. PubMed ID: 19276661
[TBL] [Abstract][Full Text] [Related]
7. Loss of CSMD1 expression is associated with high tumour grade and poor survival in invasive ductal breast carcinoma.
Kamal M; Shaaban AM; Zhang L; Walker C; Gray S; Thakker N; Toomes C; Speirs V; Bell SM
Breast Cancer Res Treat; 2010 Jun; 121(3):555-63. PubMed ID: 19669408
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of leucine zipper putative tumor suppressor 1 is associated with poor prognosis, increased cell motility and invasion, and epithelial-to-mesenchymal transition characteristics in human breast carcinoma.
Wang XX; Zhu Z; Su D; Lei T; Wu X; Fan Y; Li X; Zhao J; Fu L; Dong JT; Fu L
Hum Pathol; 2011 Oct; 42(10):1410-9. PubMed ID: 21419475
[TBL] [Abstract][Full Text] [Related]
9. The novel complement inhibitor human CUB and Sushi multiple domains 1 (CSMD1) protein promotes factor I-mediated degradation of C4b and C3b and inhibits the membrane attack complex assembly.
Escudero-Esparza A; Kalchishkova N; Kurbasic E; Jiang WG; Blom AM
FASEB J; 2013 Dec; 27(12):5083-93. PubMed ID: 23964079
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities.
Tan M; Yao J; Yu D
Cancer Res; 1997 Mar; 57(6):1199-205. PubMed ID: 9067293
[TBL] [Abstract][Full Text] [Related]
11. In vivo and in vitro effects of microRNA-27a on proliferation, migration and invasion of breast cancer cells through targeting of SFRP1 gene via Wnt/β-catenin signaling pathway.
Kong LY; Xue M; Zhang QC; Su CF
Oncotarget; 2017 Feb; 8(9):15507-15519. PubMed ID: 28099945
[TBL] [Abstract][Full Text] [Related]
12. The human complement inhibitor Sushi Domain-Containing Protein 4 (SUSD4) expression in tumor cells and infiltrating T cells is associated with better prognosis of breast cancer patients.
Englund E; Reitsma B; King BC; Escudero-Esparza A; Owen S; Orimo A; Okroj M; Anagnostaki L; Jiang WG; Jirström K; Blom AM
BMC Cancer; 2015 Oct; 15():737. PubMed ID: 26480818
[TBL] [Abstract][Full Text] [Related]
13. Reprimo as a modulator of cell migration and invasion in the MDA-MB-231 breast cancer cell line.
Buchegger K; Ili C; Riquelme I; Letelier P; Corvalán AH; Brebi P; Huang TH; Roa JC
Biol Res; 2016 Jan; 49():5. PubMed ID: 26796959
[TBL] [Abstract][Full Text] [Related]
14. MiR-630 suppresses breast cancer progression by targeting metadherin.
Zhou CX; Wang CL; Yu AL; Wang QY; Zhan MN; Tang J; Gong XF; Yin QQ; He M; He JR; Chen GQ; Zhao Q
Oncotarget; 2016 Jan; 7(2):1288-99. PubMed ID: 26595523
[TBL] [Abstract][Full Text] [Related]
15. Primary breast myoepithelial cells exert an invasion-suppressor effect on breast cancer cells via paracrine down-regulation of MMP expression in fibroblasts and tumour cells.
Jones JL; Shaw JA; Pringle JH; Walker RA
J Pathol; 2003 Dec; 201(4):562-72. PubMed ID: 14648659
[TBL] [Abstract][Full Text] [Related]
16. Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
Rennstam K; McMichael N; Berglund P; Honeth G; Hegardt C; Rydén L; Luts L; Bendahl PO; Hedenfalk I
Breast Cancer Res Treat; 2010 Jul; 122(2):315-24. PubMed ID: 19795205
[TBL] [Abstract][Full Text] [Related]
17. Increased regucalcin gene expression extends survival in breast cancer patients: Overexpression of regucalcin suppresses the proliferation and metastatic bone activity in MDA-MB-231 human breast cancer cells in vitro.
Yamaguchi M; Osuka S; Weitzmann MN; Shoji M; Murata T
Int J Oncol; 2016 Aug; 49(2):812-22. PubMed ID: 27221776
[TBL] [Abstract][Full Text] [Related]
18. The Diverse Role of CUB and Sushi Multiple Domains 1 (CSMD1) in Human Diseases.
Ermis Akyuz E; Bell SM
Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553598
[TBL] [Abstract][Full Text] [Related]
19. CERS2 suppresses tumor cell invasion and is associated with decreased V-ATPase and MMP-2/MMP-9 activities in breast cancer.
Fan SH; Wang YY; Lu J; Zheng YL; Wu DM; Zhang ZF; Shan Q; Hu B; Li MQ; Cheng W
J Cell Biochem; 2015 Apr; 116(4):502-13. PubMed ID: 25213553
[TBL] [Abstract][Full Text] [Related]
20. Different expression levels of DLK1 inversely modulate the oncogenic potential of human MDA-MB-231 breast cancer cells through inhibition of NOTCH1 signaling.
Nueda ML; Naranjo AI; Baladrón V; Laborda J
FASEB J; 2017 Aug; 31(8):3484-3496. PubMed ID: 28461338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
